Literature DB >> 3307618

Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro.

F Kawana, S Shigeta, M Hosoya, H Suzuki, E De Clercq.   

Abstract

We examined the inhibitory effect of 20 antiviral compounds, including ribavirin, on the replication of respiratory syncytial virus in HeLa and HEp-2 cell cultures. Of the compounds studied, pyrazofurin and 3-deazaguanine emerged as more potent inhibitors of respiratory syncytial virus than ribavirin. Based on their inhibitory effect on the cytopathogenicity of respiratory syncytial virus in HeLa cells, the average 50% effective dose of pyrazofurin and 3-deazaguanine for eight strains was 0.07 and 1.65 micrograms/ml, respectively; that of ribavirin was 5.82 micrograms/ml. The cytotoxicity of these compounds for HeLa cells was examined by monitoring the incorporation of radiolabeled uridine into cellular RNA. The selectivity indexes of pyrazofurin and 3-deazaguanine exceeded that of ribavirin by 70- and 11-fold, respectively. Pyrazofurin, 3-deazaguanine, and ribavirin inhibited both viral antigen expression and syncytium formation in HeLa cell cultures, as assessed by an indirect immunofluorescence assay. In these assays, pyrazofurin and 3-deazaguanine again proved more potent than ribavirin. 2,5-Diamidinoindole and carbodine were less potent than ribavirin. Various other compounds, i.e., 3-adenin-9-yl-2-hydroxypropanoic acid isobutyl ester, 3-deazauridine, 3'-C-methyluridine, 5'-deoxy-5-fluorouridine, 5-cyanoimidazole-4-carboxamide, and its ribofuranosyl derivative, did not inhibit the cytopathic effect of the Long strain of respiratory syncytial virus at concentrations greater than or equal to 125 micrograms/ml. Tubercidin, 5-chlorotubercidin, xylotubercidin, neplanocin A, thiosemicarbazone R, and 3-methylquercetine were too toxic to HeLa cells for their inhibitory effects on respiratory syncytial virus to be examined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3307618      PMCID: PMC174908          DOI: 10.1128/AAC.31.8.1225

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Immunofluorescence with respiratory syncytial virus.

Authors:  A L KISCH; K M JOHNSON; R M CHANOCK
Journal:  Virology       Date:  1962-02       Impact factor: 3.616

2.  Respiratory viral infection in childhood. A survey in general practice, Roehampton 1967-1972.

Authors:  M E Horn; E Brain; I Gregg; S J Yealland; J M Inglis
Journal:  J Hyg (Lond)       Date:  1975-04

3.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection.

Authors:  H W Kim; J O Arrobio; C D Brandt; B C Jeffries; G Pyles; J L Reid; R M Chanock; R H Parrott
Journal:  Am J Epidemiol       Date:  1973-09       Impact factor: 4.897

4.  Inhibition of rhinovirus by isatin thiosemicarbazone analogues.

Authors:  J M Gladych; J H Hunt; D Jack; R F Haff; J J Boyle; R C Stewart; R J Ferlauto
Journal:  Nature       Date:  1969-01-18       Impact factor: 49.962

5.  Respiratory syncytial virus infection and its serologic epidemiology.

Authors:  T Suto; N Yano; M Ikeda; M Miyamoto; S Takai; S Shigeta; Y Hinuma; N Ishida
Journal:  Am J Epidemiol       Date:  1965-11       Impact factor: 4.897

6.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

7.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

8.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

9.  Fluorescent cell counting as an assay method for respiratory syncytial virus.

Authors:  J H Schieble; A Kase; E H Lennette
Journal:  J Virol       Date:  1967-06       Impact factor: 5.103

10.  Biochemistry and biological effects of the pyrazofurins (pyrazomycins): initial clinical trial.

Authors:  G E Gutowski; M J Sweeney; D C DeLong; R L Hamill; K Gerzon; R W Dyke
Journal:  Ann N Y Acad Sci       Date:  1975-08-08       Impact factor: 5.691

View more
  13 in total

1.  Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins.

Authors:  M Hosoya; J Balzarini; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

2.  Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds.

Authors:  E De Clercq; M Cools; J Balzarini; R Snoeck; G Andrei; M Hosoya; S Shigeta; T Ueda; N Minakawa; A Matsuda
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1.

Authors:  Michael J Dapp; Laurent Bonnac; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

4.  SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.

Authors:  M Witvrouw; J Balzarini; C Pannecouque; S Jhaumeer-Laulloo; J A Esté; D Schols; P Cherepanov; J C Schmit; Z Debyser; A M Vandamme; J Desmyter; S R Ramadas; E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

5.  Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho- and paramyxoviruses.

Authors:  S Shigeta; S Mori; M Baba; M Ito; K Honzumi; K Nakamura; H Oshitani; Y Numazaki; A Matsuda; T Obara
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion.

Authors:  S Ikeda; J Neyts; S Verma; A Wickramasinghe; P Mohan; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Antiviral activity of diarylheptanoid stereoisomers against respiratory syncytial virus in vitro and in vivo.

Authors:  Katsuhiko Konno; Motofumi Miura; Masaharu Toriyama; Shigeyasu Motohashi; Rie Sawamura; Wataru Watanabe; Hiroki Yoshida; Masahiko Kato; Ryuichi Yamamoto; Ken Yasukawa; Masahiko Kurokawa
Journal:  J Nat Med       Date:  2013-01-24       Impact factor: 2.343

8.  Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro.

Authors:  S Shigeta; K Konno; T Yokota; K Nakamura; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

9.  Effects of protease inhibitors on replication of various myxoviruses.

Authors:  M Hosoya; S Matsuyama; M Baba; H Suzuki; S Shigeta
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.

Authors:  Cheryl L Sargel; Mohammed Aboud; Aimee Forster; Loralie J Langman; Jessica Tansmore; Bruce A Mueller; William E Smoyer; Jeffery J Auletta
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.